ArticleOncology letters2015
XRCC3 T241M polymorphism and melanoma skin cancer risk: A meta-analysis.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.
- Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and pancreatic cancer.World journal of surgical oncology · 2024Pooled it
- Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis.BioMed research international · 2022Pooled it
- Association between the XRCC3 Thr241Met Polymorphism and Gastrointestinal Cancer Risk: A Meta-AnalysisAsian Pacific journal of cancer prevention : APJCP · 2016Article
- Centenarian Exomes as a Tool for Evaluating the Clinical Relevance of Germline Tumor Suppressor Mutations.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the T241M polymorphism in the X-ray cross-complementing group 3 (XRCC3) gene has been implicated in the pathogenesis of melanoma, the results have been inconsistent. In this study, a meta-analysis was performed to assess the association of XRCC3 T241M polymorphism with melanoma. Published literature from PubMed and Embase databases was retrieved. The pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed- or random-effects models. A total of six case-control studies containing 2,133 patients and 3,141 controls were enrolled into this meta-analysis. In a combined analysis, the results revealed no significant association between XRCC3 T241M polymorphism and melanoma risk in the overall population. In the subgroup analysis by ethnicity, no significant associations between the XRCC3 T241M polymorphism and melanoma risk were identified in Caucasians. However, when the analyses were restricted to three larger studies (n>500 cases), a significant association was noted with melanoma (TT vs. MT: OR=1.20, 95% CI=1.04-1.38; dominant model: OR=0.86, 95% CI=0.75-0.98). In conclusion, the meta-analysis results suggest that the XRCC3 T241M polymorphism was associated with risk of melanoma. Further large and well-designed studies are needed to confirm this conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.